Get the Stockscreener App
0.4961
2.49%
-0.0141
Sangamo Therapeutics Inc stock is traded at $0.4961, with a volume of 2.30M.
It is down -2.49% in the last 24 hours and up +8.74% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.5102
Open:
$0.5198
24h Volume:
2.30M
Relative Volume:
0.49
Market Cap:
$116.00M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.6615
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
-0.50%
1M Performance:
+8.74%
6M Performance:
-55.97%
1Y Performance:
+25.28%
1-Day Range:
$0.4931
$0.52
1-Week Range:
$0.47
$0.52
52-Week Range:
$0.3726
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.4975 | 122.70M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.84 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.43 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.08 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.50 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
292.00 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
What analysts say about Sangamo Therapeutics Inc. stockBreakout portfolio performance - jammulinksnews.com
Is Sangamo Therapeutics Inc. a good long term investmentExceptional trading results - PrintWeekIndia
What drives Sangamo Therapeutics Inc. stock priceTremendous wealth creation - jammulinksnews.com
Sangamo Therapeutics Inc. Stock Analysis and ForecastAccelerated earnings growth - jammulinksnews.com
Why Sangamo Therapeutics Inc. stock is on top investor watchlistsAnalyst Grade Signals - beatles.ru
Hemoglobinopathies Market Set to Witness Significant Growth - openPR.com
Sangamo Therapeutics prices $23M securities offering - MSN
Why Sangamo Therapeutics Inc. stock attracts strong analyst attentionMinimized Risk Trading Plan - beatles.ru
H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data - Insider Monkey
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN) - The Globe and Mail
Sangamo rises after trial data for Fabry disease therapy - MSN
Sangamo Therapeutics (SGMO) Receives Reiterated "Buy" Rating fro - GuruFocus
Transcat: HC Wainwright Reiterates Buy, Raises PT to $116 from $116. - AInvest
Sangamo's (SGMO) Promising Phase 1/2 Gene Therapy Results for Fa - GuruFocus
Sangamo reports positive results for Fabry disease gene therapy By Investing.com - Investing.com India
Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts - insights.citeline.com
Sangamo Biosciences Approves Amendments to Equity Plan - TipRanks
Treg Cell-Based Therapies Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Rapa Therapeutics, Orca Bio, Caladrius Biosciences, Sangamo Therapeut - The Globe and Mail
Certain Warrants of Sangamo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2025. - MarketScreener
Palmetto Grain Brokerage - Palmetto Grain Brokerage
H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN
Two Sigma Investments LP Acquires 698,296 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
10 Promising Biotech Stocks to Invest in (June 2025) - Securities.io
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Zenopa
Sangamo Therapeutics’ SWOT analysis: genomic medicine firm faces cash crunch - Investing.com UK
Lazard Asset Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Captrust Financial Advisors Makes New $30,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
StockNews.com Initiates Coverage on Sangamo Therapeutics (NASDAQ:SGMO) - Defense World
Barclays Issues Pessimistic Forecast for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World
Sangamo Biosciences’ Earnings Call: Progress Amid Challenges - TipRanks
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | SGMO Stock News - GuruFocus
Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock New - GuruFocus
Sangamo Biosciences Announces $23 Million Share Offering - TipRanks
Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock News - GuruFocus
Sangamo Therapeutics (SGMO) Projects 2025 Operating Expenses Ami - GuruFocus
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights - GuruFocus
Market Setbacks: Major Stocks Face Financial Hurdles - Finimize
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics (SGMO) Announces $23M Capital Raise - GuruFocus
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):